Earlier this week semaglutide drug Wegovy was made available for prescription in New Zealand. Semaglutide originally arrived on the market in the US in 2017 as a diabetes medication but has quickly been tied to extreme weightloss.
New Scientist health reporter Grace Wade joins Jim to discuss both the benefits and risks of semaglutides.
Wegovy is a weight loss drug that is injected weekly. Photo: JENS KALAENE
